Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
0.2041
+0.0101 (5.21%)
At close: Nov 4, 2026, 4:00 PM EST
0.1990
-0.0051 (-2.50%)
After-hours: Nov 4, 2026, 4:55 PM EST
Context Therapeutics Employees
Context Therapeutics had 15 employees as of December 31, 2025. The number of employees increased by 3 or 25.00% compared to the previous year. That makes Context Therapeutics the 39,082nd largest employer in the world and 5,722nd in the United States.
Employees
15
Change (1Y)
3
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$3,063,856
Market Cap
18.75M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | 3 | 25.00% |
| Dec 31, 2024 | 12 | 7 | 140.00% |
| Dec 31, 2023 | 5 | -4 | -44.44% |
| Dec 31, 2022 | 9 | - | - |
| Jun 30, 2021 | 2 | - | - |
| Mar 31, 2021 | 2 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Seres Therapeutics | 66 |
| Acumen Pharmaceuticals | 61 |
| Kyntra Bio | 34 |
| Jasper Therapeutics | 22 |
| Quantum BioPharma | 17 |
| Actuate Therapeutics | 12 |
| Cocrystal Pharma | 10 |
CNTX News
- 1 month ago - Context Therapeutics doses first patient in CT-202 trial - TheFly
- 1 month ago - Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 - GlobeNewsWire
- 2 months ago - Context downgraded to Market Perform from Outperform at LifeSci Capital - TheFly
- 3 months ago - Context Therapeutics price target lowered to $3 from $4 at Citizens - TheFly
- 3 months ago - Context Therapeutics reports Q2 EPS (15c), consensus (9c) - TheFly
- 3 months ago - Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress - GlobeNewsWire
- 3 months ago - Context Therapeutics Quarterly report: Q2 2026 - Filings
- 3 months ago - Context Therapeutics Earnings release: Q2 2026 - Filings